Gritstone bio

Gritstone bio, founded in August 2015 and publicly listed on the Nasdaq Global Select Market under the ticker symbol GRTS since September 2018, specializes in developing next-generation vaccines for cancer and infectious diseases. The company employs a proprietary artificial intelligence platform called EDGE™ to identify T cell targets and has developed two key platforms: EDGE™ and unique delivery systems for immunotherapy. Gritstone bio’s cancer vaccines are designed to direct a robust immune response to neoantigens, with investigational programs such as GRANITE, a personalized immunotherapy, and SLATE, an off-the-shelf immunotherapy. The company collaborates with Gilead Sciences to develop a vaccine-based immunotherapy for HIV and with 2seventy bio to identify tumor-specific targets for T-cell receptor (TCR) directed cell therapies. Additionally, Gritstone bio develops vaccine candidates for COVID-19 and other common viral diseases through its CORAL program. The company operates facilities in Pleasanton, CA, which houses manufacturing capabilities; Emeryville, CA, the corporate headquarters with an immunotherapy platform research lab; and Cambridge, MA, which includes a GMP sequencing lab, immune monitoring, and mass spec immunopeptidomics capabilities. Gritstone bio uses proprietary vectors, chimpanzee adenovirus (ChAd) and self-amplifying mRNA (samRNA), in its clinical programs, aiming to instruct the immune system to recognize and attack disease targets.